Ballymore Resources (ASX: BMR) extends Torpy’s high-grade silver system as 20 drill assays remain pending
Read More Pharma Industry News Why argenx is buying Forte Biosciences before FB102 enters its bigger proof stage argenx agrees to buy Forte Biosciences for $2.2 billion. Read how FB102 could reduce Vyvgart concentration risk and reshape ARGX’s autoimmune strategy. byVenkateshJuly 31, 2026